E Fund Management Co. Ltd. Makes New Investment in CytomX Therapeutics, Inc. (NASDAQ:CTMX)

E Fund Management Co. Ltd. purchased a new position in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 6,769 shares of the biotechnology company’s stock, valued at approximately $52,000.

Several other institutional investors also recently modified their holdings of CTMX. Meeder Asset Management Inc. acquired a new position in shares of CytomX Therapeutics in the 1st quarter valued at $43,000. Lazard Asset Management LLC acquired a new position in shares of CytomX Therapeutics in the 4th quarter valued at $54,000. Citigroup Inc. boosted its holdings in shares of CytomX Therapeutics by 139.5% in the 4th quarter. Citigroup Inc. now owns 11,447 shares of the biotechnology company’s stock valued at $75,000 after buying an additional 6,667 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in CytomX Therapeutics in the 4th quarter valued at $79,000. Finally, Hsbc Holdings PLC raised its position in CytomX Therapeutics by 33.1% in the 4th quarter. Hsbc Holdings PLC now owns 15,890 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 3,954 shares during the last quarter. Institutional investors and hedge funds own 84.24% of the company’s stock.

Several analysts recently commented on the stock. Zacks Investment Research downgraded shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 7th. JPMorgan Chase & Co. started coverage on shares of CytomX Therapeutics in a research report on Monday, March 29th. They issued an “overweight” rating and a $14.00 price target for the company. Jefferies Financial Group upgraded shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, March 23rd. Finally, Barclays downgraded shares of CytomX Therapeutics from an “equal weight” rating to an “underweight” rating and cut their price objective for the stock from $9.00 to $7.00 in a research report on Friday, May 28th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $10.50.

In other news, CEO Sean A. Mccarthy sold 100,000 shares of the company’s stock in a transaction on Wednesday, March 31st. The shares were sold at an average price of $7.49, for a total transaction of $749,000.00. Following the transaction, the chief executive officer now directly owns 306,894 shares of the company’s stock, valued at approximately $2,298,636.06. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 5.80% of the company’s stock.

NASDAQ:CTMX opened at $7.22 on Friday. CytomX Therapeutics, Inc. has a fifty-two week low of $6.25 and a fifty-two week high of $10.05. The firm has a market cap of $469.38 million, a PE ratio of -5.87 and a beta of 0.70. The stock’s fifty day moving average is $8.04.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Thursday, May 6th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.03. CytomX Therapeutics had a negative net margin of 90.87% and a negative return on equity of 80.13%. On average, sell-side analysts forecast that CytomX Therapeutics, Inc. will post -1.1 earnings per share for the current fiscal year.

About CytomX Therapeutics

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.

See Also: What Does a Sell-Side Analyst Rating Mean?

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.